Tag Archives: SAGE

Oppenheimer Keeps Their Buy Rating on SAGE Therapeutics (SAGE)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $170. The company’s shares closed on Friday at $167.34, close to its 52-week high of

SAGE Therapeutics (SAGE) Receives a Buy from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) yesterday and set a price target of $170. The company’s shares closed yesterday at $165.52, close to its 52-week high of $177.14. Olson said: “SAGE

The CFO & Treasurer of SAGE Therapeutics is Exercising Options

Today it was reported that the CFO & Treasurer of SAGE Therapeutics (SAGE – Research Report), Kimi Iguchi, exercised options to buy 4,723 SAGE shares at $0.45 a share, for a total transaction value of $2,125. This recent transaction increases

The President & CEO of SAGE Therapeutics is Exercising Options

Today it was reported that the President & CEO of SAGE Therapeutics (SAGE – Research Report), Jeffrey Jonas, exercised options to buy 10,000 SAGE shares at $0.45 a share, for a total transaction value of $4,500. This recent transaction increases

Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (NASDAQ: SAGE) and Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on SAGE Therapeutics (SAGE – Research Report) and Biohaven Pharmaceutical Holding Co Ltd (BHVN – Research Report). SAGE Therapeutics (SAGE) In a report released today, Marc

SAGE Therapeutics (SAGE) Received its Third Buy in a Row

After Oppenheimer and Morgan Stanley gave SAGE Therapeutics (NASDAQ: SAGE) a Buy rating last month, the company received another Buy, this time from J.P. Morgan. Analyst Cory Kasimov maintained a Buy rating on SAGE Therapeutics yesterday and set a price